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genetic lesions such as p53 ablation, is
expected to reveal gastric cancer pre-
disposition and could provide more
detailed insight into the roles of Runx3 in
tumor initiation and progression and 
its possible interactions with cofactors.
Alternatively, a conditional Runx3 knock-
out mouse may serve this purpose. In
addition, such mouse models will allow
investigation of the extent to which loss
of RUNX3 complements or substitutes
for other lesions known from gastric can-
cers, such as E-cadherin loss, RAS
mutations, and loss of DCC. It can be
expected that this mouse model for gas-
tric cancer will greatly assist unraveling
of the underlying molecular causes for
this important widespread disease in the
coming years.
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The secrets of selective estrogen receptor modulation:
Cell-specific coregulation
A specific increase in the level of a single coactivator appears to enhance estrogen action with tamoxifen at some gene 
targets in uterine cells but not breast cells.
The discovery and development of antie-
strogens as treatments for estrogen
receptor (ER) positive breast cancer
(Lerner and Jordan, 1990) introduced a
new approach for targeted therapy with
few side effects compared to traditional
cytotoxic chemotherapy. The novel so-
called nonsteroidal antiestrogens, initial-
ly investigated during the 1960s, were all
classified as partial estrogen agonists in
the rat uterus but with a predominantly
antiestrogen action. This pharmacologic
activity in the laboratory extrapolated to
antitumor action by blocking estrogen-
stimulated breast tumor growth at the
ER. Tamoxifen was introduced clinically
during the 1970s, and the drug has had a
profound effect on patient survival. It is
estimated that 400,000 women are alive
today because of the success of tamox-
ifen treatment. However, tamoxifen is a
pioneering medicine over and above its
ability to save lives.
The recognition of selective estrogen
receptor modulation in the laboratory
during the 1980s (Jordan, 2001) has had
important implications not only for the
evaluation of the side effects associated
with tamoxifen, but also has established
the rationale for a new class of drugs, the
selective estrogen receptor modulators
(SERMs). It is now clear that SERMs
have potential as multifunctional medi-
cines. The SERMs express estrogen-like
actions in bone, lower circulating choles-
terol, but produce an antiestrogenic
action in the breast. The actions of
tamoxifen in the endometrium are impor-
tant because they illustrate the concept
of selective ER modulation. When both
breast and endometrial tumors are
implanted into immune deficient mice
(Gottardis et al., 1988), tamoxifen
enhances the growth of endometrial can-
cer but prevents the growth of breast
cancer. The tamoxifen ER complex is
perceived as an estrogen in endometrial
cancer cells but as an antiestrogen in
breast cancer. This concept translated to
the clinic with a predicted modest rise in
the incidence of endometrial cancer in
postmenopausal women during tamox-
ifen therapy. The question is, how is the
pharmacology of tamoxifen reversed in
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select target tissues?
A recent article in Science by Shang
and Brown (2002) describes two novel
differences between genes activated by
the tamoxifen ER complex in uterine or
breast cancer cells: (1) gene transcrip-
tion depends on nontraditional promoter
docking for activation, and (2) gene acti-
vation depends upon an elevated level of
a specific coregulatory protein SRC-1.
The advance is intriguing because an
understanding of the complex issue of
SERM action has such important impli-
cations in therapeutics. However, the
report by Shang and Brown is part of an
evolving story that will continue to take
many twists and turns before the secrets
of SERMs are fully deciphered.
Berry and coworkers (Berry et al.,
1990) were the first to show that the
estrogen-like effects of tamoxifen com-
plexes were dependent both on the pro-
moter and the cell context. The AF-1
region at the N-terminal end of the ER
was identified as the site for the superin-
duction of the tamoxifen ER complex sig-
nal pathways in the correct context.
Current thinking about SERM action
has focused attention on specific coregu-
lators of signal transduction. SERMs 
can produce specific conformational
changes in the external shape of the ER
complex that in turn influence the binding
of corepressors to prevent transcription
or coactivators to enhance transcription
(Katzenellenbogen et al., 1996) (Figure
1). Shang and Brown (2002) provide
compelling evidence that the up- or
downregulation of the coactivator SRC-1
can increase or decrease the estrogen-
like action of the tamoxifen ER complex in
either breast or endometrial cancer cells.
The coactivator model is based on the law
of mass action; i.e., more coactivator at a
site activates, and less coactivator deacti-
vates, the SERM receptor complex.
However, the SERM raloxifene is not influ-
enced by these molecular maneuvers.
Raloxifene, a chemical cousin of tamox-
ifen, selectively enhances estrogen-like
actions in bones, breast, and liver (to
lower circulating cholesterol levels), but
most importantly has less estrogen-like
activity in the uterus. This fact supports
the author’s model, but what is the differ-
ence between tamoxifen and raloxifene?
The key appears to be the surface
amino acid aspartate at position 351 in
ERα. This aspartate has only a weak
interaction with the antiestrogenic side
chain of tamoxifen. In contrast, the antie-
strogenic sidechain of raloxifene com-
pletely shields and neutralizes the
charge. The exposure of a surface
charge could therefore be connected
with the promiscuous estrogen-like prop-
erties of the tamoxifen ER complex.
Indeed, molecular manipulation of the
raloxifene ER complex by changing the
charge at 351 and the side chain of
raloxifene results in the modulation of the
antiestrogenic complex to an estrogen
(Liu et al., 2002). It is argued that an
increased charge at 351 prevents 
the binding of corepressor modules
(Yamamoto et al., 2001) (Figure 1).Thus,
the give and take of coregulators by the
SERM receptor complex can explain
some, but not all, of the target site specif-
ic actions of SERMs.
A study of cancer can provide an
insight into the physiology of SERM
action, because the malignant cell has
such a profound ability to adapt its bio-
chemistry to survive. Tamoxifen has 
a unique form of acquired drug resis-
tance in breast and uterine cancer
expressed as tamoxifen-stimulated
growth. Raloxifene is crossresistant with
tamoxifen in breast and endometrial can-
cer, so a simple increase of coactivators
or loss of corepressors may not be the
whole story.
Cell surface signaling through the
epidermal growth factor receptor family
is associated with increased phosphory-
lation pathways that promote growth.
The estrogen-like action of the tamoxifen
ER complex can be modulated by phos-
phorylation cascades that either con-
verge on AF-1 or the coactivators (Feng
et al., 2001). Indeed, the fact that estro-
gen can downregulate HER-2/neu (a
member of the EGFR family) synthesis
by sequestering SRC-1, but tamoxifen
can enhance the transcription of HER-
2/neu by releasing excess SRC-1 from
the SERM ERα complex, creates an
intriguing model to facilitate the develop-
ment of drug resistance and the self-sus-
taining activation of the tamoxifen ER
complex (Newman et al., 2000).The cen-
tral role for SRC-1 in the expression of
the estrogen-like effects of tamoxifen
identified by Shang and Brown (2002)
creates a starting point to examine the
possibility of a cell surface phosphoryla-
tion cascade for the modulation of the
SERM ER complex in endometrial can-
cer. It is therefore appropriate to take an
integrated view of the target site activa-
Figure 1. Integrated mechanism for the tar-
get site specific action of SERMs in breast or
uterine cancer
The two extremes of antiestrogenic or full
estrogenic actions are shown. Estrogen-like
actions could occur in cells expressing an
excess of coactivators (CoAs) and/or a
decrease in corepressors (CoRs). The
charged surface of a tamoxifen ER complex
at AF2b prevents CoR binding. The estro-
genic action would be amplified by surface
signaling with dimers of epidermal growth
factor receptor (EGFR) and HER2/neu acti-
vating tyrosine kinases (tks). The phosphory-
lation cascade can activate AF-1 on ERα
directly or activate the excess of CoAs in a
high ER environment. Reduced levels of ER
prevent the signal transduction pathway
and promote antiestrogenic actions in a sur-
face silent cell.
CANCER CELL : APRIL 2002 217
P R E V I E W S
tion of genes by SERMs in cancer
(Figure 1). A decrease in coactivators
(CoA) in a corepressors (CoR) dominant
environment predestines antiestrogen
action in the cell with a silent surface. In
contrast, a cell where the SERM ER
complex is charged and cannot bind
CoRs will be predestined to have estro-
gen-like effects. If CoAs were increased
and the cell surface was activated to pro-
duce a phosphorylation cascade, this
would be predicted to enhance the estro-
gen-like of an appropriate SERM.
The successful clinical application of
tamoxifen has driven research to seek
clinical improvements and understand
the molecular mechanisms of SERMs.
Tamoxifen has been referred to as the
Rosetta Stone with which to decipher
molecular mechanisms at the ER that
have importance in health care. Now the
expectation is to develop a series of mul-
tifunctional medicines to treat and, most
importantly, prevent a spectrum of dis-
eases ranging from breast cancer and
osteoporosis to coronary heart disease.
The Shang and Brown article is yet
another step toward that goal.
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